Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.33 |
| ▸ | MYLK | Q15746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420947 | 0.82 | LMNA (0.41) | LMNAKMT2AHTTRETPRKCE | |
| SCHEMBL23534347 | 0.81 | LMNA (0.36) | LMNARET | |
| SCHEMBL17490835 | 0.81 | KMT2A (0.48) | LMNAKMT2AHTTRETALDH1A1 | |
| SCHEMBL17502182 | 0.77 | HTT (0.41) | KMT2AHTTRETMAPTTDP1 | |
| SCHEMBL28527117 | 0.77 | ALDH1A1 (0.39) | LMNAKMT2AHTTRETALDH1A1 | |
| SCHEMBL30744962 | 0.74 | OPRK1 (0.38) | LMNAHTTALDH1A1MAPTAPEX1 | |
| SCHEMBL20944537 | 0.74 | OPRK1 (0.38) | LMNAHTTALDH1A1MAPTAPEX1 | |
| SCHEMBL15773977 | 0.74 | KMT2A (0.43) | LMNAKMT2AHTTRETALDH1A1 | |
| SCHEMBL29337230 | 0.73 | HTT (0.35) | KMT2AHTTALDH1A1MEN1 | |
| SCHEMBL24502939 | 0.72 | KMT2A (0.41) | LMNAKMT2AHTTRETALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| EP-3207043-B3 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3207043-B3 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3207043-B1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10087184-B2 | Dihydropyrrolopyridine inhibitors of RORγ | VITAE PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| US-9796710-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796710-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796710-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3207043-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-9481674-B1 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481674-B1 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2016061160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016061160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | LMNA 4465/4885KMT2A 3277/4885HTT 4513/4885 |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | LMNA 4408/4885KMT2A 3177/4885HTT 4608/4885 |
| US-10087184-B2 | Dihydropyrrolopyridine inhibitors of RORγ | RORC, RORB, RORA | LMNA 4735/4885KMT2A 3716/4885HTT 4295/4885 |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | LMNA 4465/4885KMT2A 3277/4885HTT 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.